• Alessandra Siegmann, Dirk Bottke, Julia Faehndrich, Maike Brachert, Gunnar Lohm, Kurt Miller, Detlef Bartkowiak, Wolfgang Hinkelbein, and Thomas Wiegel.
• Department of Radiation Oncology, Charité Universitätsmedizin, Berlin, Germany.
• Radiother Oncol. 2012 May 1; 103 (2): 239-43.

PurposeSalvage radiotherapy (SRT) is applied routinely in patients with biochemical relapse after radical prostatectomy (RP). However, only ∼30% of these patients achieve a durable response after 10 years. As a standard, 66 Gy are given, ideally with a PSA below 0.5 ng/ml. We tried to determine more precisely the optimal PSA for starting SRT.Material And MethodsIn 301 prostate cancer patients without hormonal treatment, we analysed the impact on the biochemical response (bNED) to SRT of two pre-SRT PSA levels, namely below or above the median of 0.28 ng/ml.ResultsThe median follow-up time for the entire group was 30 months. In 151 patients, SRT commenced at a PSA ≤ 0.28 ng/ml, in 150 at > 0.28 ng/ml. Eighty-two patients (27%) developed biochemical progression during follow up. The calculated two-year bNED was 74% for the entire group, 78% versus 61% for a PSA ≤ or > 0.28 ng/ml, respectively. In multivariate analysis, pT(3b), resection status, pre-SRT PSA dichotomized at median, PSA post-SRT undetectable, and PSA doubling time were statistically significant independent predictors of progression after SRT.ConclusionsOur findings suggest that a PSA of ≤ 0.28 ng/ml improves bNED compared with a PSA before SRT of > 0.28 ng/ml.Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

15 keywords...

hide…